RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Xynomic Pharma, a Raleigh-Shanghai oncology company, presented positive data from exceptional responders in a long-term follow-up of its lead drug abexinostat (ABX) plus pazopanib. Xynomic says data from the Phase Ib trial show that (1) durable responses with ABX + PAZ are achievable, even in patients with PAZ- and VEGF-refractory RCC and other solid tumor malignancies, and (2) host factors including HDAC expression and acetylation status may identify the patients most likely to benefit from the combination therapy.
Source: China Biotoday
